Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04392778
Other study ID # Bak. Sadi Konuk-Istinye Uni.
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date April 1, 2020
Est. completion date November 30, 2020

Study information

Verified date May 2020
Source SBÜ Dr. Sadi Konuk Egitim ve Arastirma Hastanesi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to use the regenerative and repair abilities of stem cells to fight against the harmful effects of the novel coronavirus Covid-19 and therefore develop a treatment strategy. It is known that fatalities from this virus is largely caused by its damage to lungs and other organs. As the disease progresses, these organs fail and lead to mortality. Our hope is that the stem cell transplantation from healthy donors will repair the damage caused by the virus and result in a healthy recovery.


Description:

Introduction: The COVID-19 corona virus epidemic has spread from Wuhan, China to the whole world, and has been declared a pandemic by WHO worldwide. In severe patients, ARDS and multiple organ failure can be seen. This condition is associated with cytokine storm in the body. When the virus invades the body, dentric cells can activate macrophages, lymphocytes and natural killer cells. Mesenchymal stem cells (MKH) not only inhibit the abnormal activation of T lymphocytes and macrophages, but also encourage them to differentiate into regulatory T cell subsets (Treg) clusters and anti-inflammatory macrophages. MSCs application proved therapeutic efficiency during influenza infection resulting in reduced impairment of alveolar fluid clearance and lung injury. This was attributed towards attenuation of pro-inflammatory cytokine secretion, inflammatory cell recruitment and increased alveolar macrophages content. Aim of study: 1. To provide immune modulation to patients with COVID-19 who are taken to intensive care and resistant to treatment by performing MSCs transplantation and to reduce the damage caused by cytokin storm to tissues and organs, 2. Correcting immunosuppression in patients and increasing the fight against COVID-19 virus by CD4+T, CD+8T cellular cell arrangement, 3. It is to accelerate the recovery in organ damage by increasing growth factors by means of MSCs. Materials and method: Patients diagnosed with COVID-19 infection as clinically, radiologically and laboratory-wise will be divided into three groups: Group 1: patients that are not on a ventilator (n=10) Group 2: patients that are on a ventilator and will receive saline injections (n=10) Group 3: patients that are on a ventilator and will receive MSC transplantation injections (n=10) Mesenchymal stem cells originating from allogenic umbilical cord produced under GMP conditions will be administered in 3 times, with doses indicated below, intravenously within 1 week. Dose: 1. Application: 3 million cells / kg IV ---------------------------------------- --------- 1 day 2. Application: 3 million cells / kg IV ---------------------------------------- --------- 3. Day 3. Application: 3 million cells / kg IV ---------------------------------------- --------- 6. Day The blood will be analyzed for the expression levels of growth factors, including vascular endothelial growth factor, fibroblast growth factor, platelet derived-growth factor, epidermal growth factor, transforming growth factor beta, hepatocyte growth factor, nerve growth factor, VEGF receptor (VEGFR), angiopoietin1 (Angpt-1), and Angpt-2, using sandwich enzyme-linked immune sorbent assays (ELISAs). Investigators also analyzed the caspase-3 system in the blood. immunoassay kits will be used for analyses in accordance with the manufacturer's instructions. Biochemical parameters of the liver, such as alanine transaminase (ALT), aspartate transaminase (AST), total protein, albumin, total bilirubin, direct bilirubin, and alkaline phosphatase (ALP) levels, will be measured in the venous blood samples. Proinflammatory (IL1-β, IL-6, TNFα, INF-γ) and anti-inflammatory (IL-2, IL-4, IL-10, IL-13) cytokines will be examined in venous blood in order to determine the immune modulatory effect of stem cells. CD4 + T, CD4 + T killer cells Granulocyte macrophage colony factor BLC-2 VEGF-R angiopoetin-1, angiopoetin-2 Total antioxidant capacity (TAC) Total oxidant capacity (TOC).


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date November 30, 2020
Est. primary completion date November 1, 2020
Accepts healthy volunteers No
Gender All
Age group 40 Years to 60 Years
Eligibility Inclusion Criteria: - 40-60 years old male or female - Confirmed 2019-nCoV infection with RT-PCR Laboratory test - Confirmed Pneumonia with chest radiography and computer tomography - and any of the following criteria: 1. Shortness of breath (RR =30/min) 2. Resting finger oxygen saturation 93% 3. Arterial oxygen partial pressure (PaO2)/oxygen absorption concentration (FiO2) = 300MMHG 4. Advancing of focus in Pulmonary imaging to >50% in 24-48 hours Exclusion Criteria: - Those who are not pregnant, breastfeeding and pregnant but who do not take effective contraceptive measures; - Patients with malignant tumors, other serious systemic diseases and psychosis; - Informed consent is not given or does not comply with the test requirements. - Co-infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory infection virus. - Pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or co-infection of HIV, tuberculosis, influenza virus, adenovirus and other respiratory infection virus. - Obstructive HABP / VABP caused by lung cancer or other known causes; Long-term history of use of immunosuppressive agents; - History of epilepsy and need for continuous anticonvulsant therapy or anticonvulsant therapy taken within 3 years; - Invasive ventilation - Shock - Other organ failures

Study Design


Intervention

Biological:
MSC Treatment
Protocol length: 1 week Doses: Application: 3 million cells/kg IV-------------------------------------------------0 day Application: 3 million cells/kg IV ------------------------------------------------3rd day Application: 3 million cells/kg IV -------------------------------------------------6th day will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.
Saline Control
Saline will be given to patients positively, clinically and radiologically diagnosed with COVID-19, followed with 3 months observation.

Locations

Country Name City State
Turkey Istinye University Istanbul
Turkey SBÜ Dr. Sadi Konuk Egitim ve Arastirma Hastanesi Istanbul

Sponsors (4)

Lead Sponsor Collaborator
SBÜ Dr. Sadi Konuk Egitim ve Arastirma Hastanesi Istinye University, Liv Hospital (Ulus), Regenerative Medicine and Stem Cell Production Center Liv MedCell

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical improvement Improvement of clinical symptoms related to Covid-19 infection (fever, pneumonia, shortness of breath) 3 months
Secondary Lung damage improvement Improvement of lungs assessed by CT Scan 3 months
Secondary Sars-Cov-2 viral infection laboratory test Negative, measured by RT-PCR laboratory tests for the virus 3 months
Secondary Blood test Cell types and numbers 3 months
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3